The pharmaceutical company ‘AstraZeneca’ said, the antibody-based cocktail of the company for the prevention and treatment of the novel corona virus had been showing to retain the neutralization activity against the Omicron corona virus variants that is including the highly contagious BA.2 sub variant of the Omicron in a study conducted by an independent lab.
The data from the study has been showing that, the therapy has decreased the amount of the novel corona virus that was detected in the samples of all the tested sub-variants of the Omicron covid-19 variant in the lungs of the mice, as said by the company.
The therapy known as Evusheld had been tested against the sub-variants of the Omicron covid-19 variant and it had also shown the limit of the inflammation in the lungs.
John Perez, senior executive of AstraZeneca said that, the findings has also been further supporting the Evusheld therapy as a potential and important option for the purpose providing help in protecting the vulnerable patients such as the immune-compromised people, who can possibly face the poor outcomes if they had to become infected with the novel corona virus.
Last week, the World Health Organization (WHO) said that, the figures has been showing a worldwide increase in the novel corona virus cases can possibly herald a much larger program as the Omicron and its sub-variants spreading rapidly among the easing of the covid-19 restrictions and testing.
